Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pulmonx Corp
(NQ:
LUNG
)
6.120
-0.220 (-3.47%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pulmonx Corp
< Previous
1
2
3
4
5
Next >
Where Pulmonx Stands With Analysts
August 03, 2022
Within the last quarter, Pulmonx (NASDAQ:LUNG) has observed the following analyst ratings:
Via
Benzinga
Pulmonx: Q2 Earnings Insights
August 02, 2022
Pulmonx (NASDAQ:LUNG) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Pulmonx beat estimated earnings by...
Via
Benzinga
Earnings Preview: Pulmonx
August 01, 2022
Pulmonx (NASDAQ:LUNG) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Pulmonx will report...
Via
Benzinga
Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference
July 27, 2022
From
Pulmonx Corporation
Via
Business Wire
Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022
July 19, 2022
From
Pulmonx Corporation
Via
Business Wire
Recap: Pulmonx Q4 Earnings
February 23, 2022
Pulmonx (NASDAQ:LUNG) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Pulmonx...
Via
Benzinga
Earnings Scheduled For November 2, 2021
November 02, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...
Via
Benzinga
Earnings Scheduled For August 2, 2022
August 02, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
July 11, 2022
Upgrades
Via
Benzinga
Pulmonx: Q1 Earnings Insights
May 03, 2022
Pulmonx (NASDAQ:LUNG) reported its Q1 earnings results on Tuesday, May 3, 2022 at 05:05 PM. Here's what investors need to know about the announcement. Earnings Pulmonx missed estimated earnings by...
Via
Benzinga
Where Pulmonx Stands With Analysts
February 25, 2022
Within the last quarter, Pulmonx (NASDAQ:LUNG) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1...
Via
Benzinga
92 Biggest Movers From Friday
May 09, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...
Via
Benzinga
55 Stocks Moving In Friday's Mid-Day Session
May 06, 2022
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
Via
Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
February 24, 2022
Gainers Indonesia Energy Corporation Limited (NYSE: INDO) shares climbed 66.7% to $12.55 following a 16% surge on Wednesday. Camber Energy, Inc. (NYSE: CEI) rose 45.2% to $0....
Via
Benzinga
Global Stocks, Futures Crash; Nasdaq In Bear Market, Oil Soars Above $105 On Russia Attack
February 24, 2022
U.S. stock index futures crashed along with global markets on Thursday as Russia’s assault on Ukraine sent investors fleeing risky assets, while the tech-heavy Nasdaq was set to open in a bear market.
Via
Talk Markets
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
December 08, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...
Via
Benzinga
Pulmonx Corporation (LUNG) Q3 2021 Earnings Call Transcript
November 03, 2021
LUNG earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Chief Financial Officer Of Pulmonx Makes $224.56 Thousand Sale
September 22, 2021
Derrick Sung, Chief Financial Officer at Pulmonx (NASDAQ:LUNG), made a large insider sell on September 21, according to a new SEC filing. What Happened: A Form 4 filing from the U...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/COPD Treatment
September 21, 2021
From
Pulmonx Corporation
Via
Business Wire
3 Healthcare Stocks That Might Skyrocket When COVID Is Over
September 07, 2021
Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?
Via
The Motley Fool
Exposures
COVID-19
Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment
August 20, 2021
From
Pulmonx Corporation
Via
Business Wire
Return on Capital Employed Overview: Pulmonx
August 20, 2021
After pulling data from Benzinga Pro it seems like during Q2, Pulmonx (NASDAQ:LUNG) brought in sales totaling $12.20 million. However, earnings decreased 0.58%, resulting in a...
Via
Benzinga
Pulmonx Corporation (LUNG) Q2 2021 Earnings Call Transcript
August 04, 2021
LUNG earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
August 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema
July 27, 2021
From
Pulmonx Corporation
Via
Business Wire
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
May 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.